



Mayo Clinic

Consolidated Financial Report
Years Ended December 31, 2020 and 2019



Mayo Clinic

Contents

Independent auditor's report	1
Consolidated financial statements	
Consolidated statements of financial position	3
Consolidated statements of activities	4
Consolidated statements of cash flows	5
Notes to consolidated financial statements	6

Report of Independent Auditors

Board of Trustees
Mayo Clinic

We have audited the accompanying consolidated financial statements of Mayo Clinic (“the Clinic”), which comprise the consolidated statements of financial position as of December 31, 2020 and 2019, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

Auditor’s Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Mayo Clinic at December 31, 2020 and 2019, and the consolidated results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.

Ernst & Young LLP

February 19, 2021



Consolidated Statements of Financial Position
December 31, 2020 and 2019 (In Millions)

	2020	2019
Assets		
Current assets:		
Cash and cash equivalents	\$ 72	\$ 48
Accounts receivable for medical services	1,756	2,020
Securities lending collateral	2	1
Other receivables	576	458
Other current assets	252	201
Total current assets	2,658	2,728
Investments	14,320	11,135
Investments under securities lending agreement	38	19
Other long-term assets	1,204	1,023
Property, plant and equipment, net	4,964	4,834
Total assets	\$ 23,184	\$ 19,739
Liabilities and net assets		
Current liabilities:		
Accounts payable	\$ 584	\$ 512
Accrued payroll	797	667
Accrued employee benefits	163	158
Deferred revenue	90	43
Long-term variable-rate debt	620	710
Mandatory tender debt	135	—
Securities lending payable	2	1
Other current liabilities	470	473
Total current liabilities	2,861	2,564
Long-term debt, net of current portion	3,097	2,647
Accrued pension and postretirement benefits, net of current portion	2,897	2,500
Other long-term liabilities	1,964	1,634
Total liabilities	10,819	9,345
Net assets:		
Without donor restrictions	8,016	6,679
With donor restrictions	4,349	3,715
Total net assets	12,365	10,394
Total liabilities and net assets	\$ 23,184	\$ 19,739

See notes to consolidated financial statements.



Consolidated Statements of Activities **Years Ended December 31, 2020 and 2019 (In Millions)**

	2020			2019		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Revenue, gains and other support:						
Medical service revenue	\$ 11,501	\$ —	\$ 11,501	\$ 11,604	\$ —	\$ 11,604
Grants and contracts	569	—	569	568	—	568
Investment return allocated to current activities	238	32	270	221	26	247
Contributions available for current activities	91	258	349	60	211	271
Other	1,221	—	1,221	1,018	—	1,018
Net assets released from restrictions	246	(246)	—	270	(270)	—
Total revenue, gains and other support	13,866	44	13,910	13,741	(33)	13,708
Expenses:						
Salaries and benefits	8,064	—	8,064	7,670	—	7,670
Supplies and services	4,099	—	4,099	4,076	—	4,076
Depreciation and amortization	611	—	611	587	—	587
Facilities	276	—	276	290	—	290
Finance and investment	132	—	132	133	—	133
Total expenses	13,182	—	13,182	12,756	—	12,756
Income (loss) from current activities	684	44	728	985	(33)	952
Noncurrent and other items:						
Contributions not available for current activities, net	(21)	250	229	(22)	278	256
Unallocated investment return, net	1,144	340	1,484	711	255	966
Income tax expense	(40)	—	(40)	(24)	—	(24)
Benefit credit	62	—	62	134	—	134
Other	4	—	4	(4)	—	(4)
Total noncurrent and other items	1,149	590	1,739	795	533	1,328
Increase in net assets before other changes in net assets	1,833	634	2,467	1,780	500	2,280
Pension and other postretirement benefit adjustments	(496)	—	(496)	(1,038)	—	(1,038)
Increase in net assets	1,337	634	1,971	742	500	1,242
Net assets at beginning of year	6,679	3,715	10,394	5,937	3,215	9,152
Net assets at end of year	\$ 8,016	\$ 4,349	\$ 12,365	\$ 6,679	\$ 3,715	\$ 10,394

See notes to consolidated financial statements.



Consolidated Statements of Cash Flows
Years Ended December 31, 2020 and 2019 (In Millions)

	2020	2019
Cash flows from operating activities:		
Cash from medical services	\$ 10,904	\$ 10,681
Cash from external lab services	861	731
Cash from grants and contracts	555	522
Cash from benefactors	271	217
Cash from other activities	1,052	816
Cash for salaries and benefits	(7,827)	(7,648)
Cash for supplies, services, and facilities	(4,369)	(4,271)
Interest and dividends received	145	203
Interest paid	(115)	(117)
Income taxes paid	(6)	(34)
Net cash provided by operating activities	1,471	1,100
Cash flows from investing activities:		
Purchase of property, plant and equipment	(642)	(723)
Purchases of investments	(5,913)	(3,274)
Sales and maturities from investments	4,463	2,735
Investment in joint venture	(50)	—
Net cash used in investing activities	(2,142)	(1,262)
Cash flows from financing activities:		
Restricted gifts, bequests and other	214	252
Borrowing on long-term debt	630	—
Payment of long-term debt	(134)	(63)
Payment on leases	(15)	(8)
Medicare advance payments	915	—
Return of Medicare advance payments	(915)	—
Net cash provided by financing activities	695	181
Net increase in cash and cash equivalents	24	19
Cash and cash equivalents at beginning of year	48	29
Cash and cash equivalents at end of year	\$ 72	\$ 48

See notes to consolidated financial statements.

Note 1. Organization and Summary of Significant Accounting Policies

Organization: Mayo Clinic and its Arizona, Florida, Iowa, Minnesota and Wisconsin affiliates (the Clinic) provide comprehensive medical care and education in clinical medicine and medical sciences and conduct extensive programs in medical research. The Clinic also provides hospital and outpatient services, and at each major location, the clinical practice is closely integrated with advanced education and research programs. The Clinic and most of its subsidiaries have been determined to qualify as tax-exempt organizations under Section 501(c)(3) of the Internal Revenue Code (the Code) and as a public charity under Section 509(a)(2) of the Code.

Basis of presentation: Included in the Clinic's consolidated financial statements are all of its wholly owned or wholly controlled subsidiaries. All significant intercompany transactions have been eliminated in consolidation. In addition, these statements follow generally accepted accounting principles applicable to the not-for-profit industry as described in the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) *Topic 958, Not-for Profit Entities*.

Certain reclassifications have been made to the 2019 consolidated financial statements to conform with classifications used in 2020. The reclassifications had no significant effect on total assets, total liabilities, total revenue or total change in net assets previously reported.

Use of estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

New Accounting Standard:

Effective January 1, 2020, the Clinic adopted FASB Accounting Standards Update (ASU) No. 2018-13, *Fair Value Measurement (Topic 820)*. This ASU improves the effectiveness of the notes to financial statements through changes in the disclosure requirements for fair value measurement. The adoption of this ASU did not materially impact the consolidated financial statements.

New Accounting Standards Not Yet Adopted:

In August 2018, the FASB issued ASU No. 2018-14, *Compensation - Retirement Benefits - Defined Benefit Plans (Topic 715)*. This ASU modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The ASU is effective January 1, 2021 and will be applied using a retrospective approach. Adoption of this ASU will not have a significant impact on the consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, *Intangibles - Goodwill and Other, Internal-Use Software (Subtopic 350-40), Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract*. The primary effect of adopting this ASU will be capitalization of implementation costs incurred in hosting arrangements that are service contracts and subsequent amortization expense in the consolidated statements of activities. The ASU is effective

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

January 1, 2021 and will be applied using a prospective approach. The Clinic is currently assessing the impact of this ASU on its consolidated financial statements.

In September, 2020, the FASB issued ASU No. 2020-07, *Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets (Topic 958)*. This ASU requires presentation of contributed nonfinancial assets as a separate line in the consolidated statement of activities, apart from contributions of cash or other financial assets. The ASU is effective January 1, 2022 and will be applied on a retrospective basis. The Clinic is currently assessing the impact of this ASU on its consolidated financial statements.

Cash and cash equivalents: Cash and cash equivalents include currency on hand, demand deposits with banks or other financial institutions, and short-term investments with maturities of three months or less from the date of purchase, which are not managed by the Clinic's investment managers.

Accounts receivable for medical services: Accounts receivable for medical services are based upon the estimated amounts expected to be paid from patients and third-party payors.

Inventories: Inventories, consisting primarily of medical supplies and pharmaceuticals, are stated at the lower of cost or net realizable value.

Investments: Investments in equity and debt securities, including alternative investments, are recorded at fair value (Notes 4 and 5). Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Realized gains and losses are calculated based on the average cost method. Investment income or loss (including realized and unrealized gains and losses on investments, interest and dividends) is included in the consolidated statements of activities.

Alternative investments (principally limited partnership interests in absolute return, hedge, private equity, real estate and natural resources funds), represent the Clinic's ownership interest in the respective partnership, which is valued at fair value based on net asset value (NAV) obtained from fund manager statements and historically audited financial statements. The investments in alternative investments may individually expose the Clinic to securities lending, short sales, and trading in futures and forward contract options and other derivative products. The Clinic's risk is limited to the investment's carrying value.

It is the Clinic's intent to maintain a long-term investment portfolio to support research, education and other activities. Accordingly, the total investment return is reported in the consolidated statements of activities in two categories. The investment return allocated to current activities is determined by a formula, which involves allocating five percent of a three-year moving average of investments related to endowments, and the matching of financing costs for the assets required for operations. Management believes this return is approximately equal to the real return that the Clinic expects to earn on its investments over the long term. The unallocated investment return, included in noncurrent and other

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

items in the consolidated statements of activities, represents the difference between the total investment return and the amount allocated to current activities, net of investment costs.

Property, plant and equipment: Property, plant and equipment are carried at cost if purchased or at fair value on the date received through affiliation or donation, less accumulated depreciation. Plant and equipment are depreciated over their estimated useful lives, ranging from three to fifty years using the straight-line method. Depreciation expense includes amortization of assets recorded under capital leases.

Costs associated with the development and installation of internal-use software are accounted for in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Subtopic 350-40)* of the FASB ASC. Accordingly, internal-use software costs are expensed or capitalized and amortized according to the provisions of the accounting standard.

Leases: The Clinic determines if an arrangement is a lease at inception. Operating leases are included in other long-term assets, other current liabilities, and other long-term liabilities in the consolidated statements of financial position. Finance leases are included in property, plant and equipment, other current liabilities, and other long-term liabilities in the consolidated statements of financial position.

Right-of-use (ROU) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, the Clinic uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The implicit rate is used when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain the Clinic will exercise the option.

The Clinic defines a short-term lease as any lease arrangement with a lease term of twelve months or less that does not include an option to purchase the underlying asset. Short-term lease payments are recognized as expense on a straight-line basis over the lease term and variable lease payments in the period in which the obligation is incurred.

The Clinic has lease arrangements with lease and non-lease components, which are generally accounted for separately, except the Clinic has elected the practical expedient to not separate non-lease components for real estate leases. Additionally, for certain equipment leases, the Clinic applies a portfolio approach to effectively account for the ROU assets and liabilities.

Deferred revenue: Deferred revenue consists of payments received in advance for grant, subscription and tuition revenue. Deferred revenues are subsequently recognized as revenue in accordance with the Clinic's revenue recognition policies.

Deferred compensation: The Clinic offers eligible employees a nonqualified, tax-deferred compensation retirement plan. Employees defer compensation into the plan on a pretax basis. For the most part, the plan operates similar to a defined contribution plan.

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Asset retirement obligations: The Clinic accounts for the estimated cost of legal obligations associated with long-lived asset retirements in accordance with *Asset Retirement and Environmental Obligations (Topic 410)* of the FASB ASC. The asset retirement liability, recorded in other long-term liabilities, is accreted to the present value of the estimated future costs of these obligations at the end of each period.

Net assets: Net assets, revenues, gains, and losses are classified based on the existence or absence of donor or grantor imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions - Net assets available for use in general operations and not subject to donor restrictions. The governing board has designated, from net assets without donor restrictions, net assets for an operating reserve and board-designated endowment.

Net Assets With Donor Restrictions - Net assets subject to donor imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. Gifts of long-lived assets and gifts of cash restricted for the acquisition on long-lived assets are recognized as revenue when received. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both.

Medical service revenue: Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care.

Grants and contracts: Reciprocal grants and contracts revenue is recognized when the expenses have been incurred for the purpose specified by the grantor or in accordance with the terms of the agreement.

Contributed grants and contracts revenue is recorded as conditions are met or immediately if deemed an unconditional contribution. Grant and contract amounts due to the Clinic are included in other receivables.

Charity and uncompensated care: The Clinic provides health care services to patients who meet certain criteria under its Charity Care Policy without charge or at amounts less than established rates. Since the Clinic does not pursue collection of these amounts, they are not reported as revenue. The estimated cost of providing these services was \$89 and \$96 in 2020 and 2019, respectively, calculated by multiplying the ratio of cost to gross charges for the Clinic by the gross uncompensated charges associated with providing care to charity patients. In addition to the charges related to the direct patient care provided under the Clinic's Charity Care Policy, the Clinic has programs offered to benefit the broader community and other governmental reimbursement programs. The Clinic also participates in various state Medicaid programs for indigent patients. The estimated unreimbursed cost of providing services related to Medicaid programs totaled \$540 and \$494 in 2020 and 2019, respectively.

Contributions: The Clinic classifies contributions that are available for current activities as revenue, based on the lack of specific donor restriction or the presence of donor restrictions and the ability of the

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Clinic to meet those restrictions within the year. Contributions of a perpetual nature or not available for current activities are classified in noncurrent and other items in the consolidated statements of activities. Development expenses of \$48 (\$27 allocated to current and \$21 allocated to noncurrent) and \$47 (\$25 allocated to current and \$22 allocated to noncurrent) were incurred in 2020 and 2019, respectively. The current portion is recorded in expenses, and the noncurrent portion is netted against contributions not available for current activities in the consolidated statements of activities. Unconditional promises to give and contributions are reported at fair value at the time of the gift. An allowance for uncollectible pledges receivable is estimated, based on a combination of historical experience and specific identification. Conditional promises to give are recognized at fair value when the barriers to entitlement are overcome or the possibility that a condition will not be met is remote.

The Clinic periodically receives works of art from various benefactors. These items are unique in nature and are held on display for the benefit and enjoyment of the Clinic's patients. It is the Clinic's policy to neither capitalize contributed works of art nor record the related contribution revenue.

Income from current activities: The Clinic's policy is to include in income from current activities all medical service and other revenue, grants and contracts, investment return allocated to current activities, contributions available for current activities, net assets released from restrictions, and substantially all expenses. Contributions not available for current activities, unallocated investment return, income tax expense, benefit credit, and those items not expected to recur on a regular basis are included in noncurrent and other items in the consolidated statements of activities.

Subsequent events: The Clinic evaluated events and transactions occurring subsequent to December 31, 2020 through February 19, 2021, the date of issuance of the consolidated financial statements. During this period, there were no subsequent events requiring recognition in the consolidated financial statements. Additionally, there were no unrecognized events requiring disclosure.

Notes to Consolidated Financial Statements (In Millions)

Note 2. Liquidity and Availability

Financial assets available for general expenditure within one year of the consolidated statement of financial position date are comprised of the following at December 31:

	2020	2019
Cash and cash equivalents	\$ 72	\$ 48
Accounts receivable	1,756	2,020
Promises to give	234	185
Grants receivable	134	114
Other receivables	208	159
Investments	8,878	6,997
Total financial assets available within one year	<u>\$ 11,282</u>	<u>\$ 9,523</u>

As part of a liquidity management plan, the Clinic has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Cash in excess of daily requirements is invested in short-term investments. In the event of an unanticipated liquidity need, the Clinic has \$300 and \$100 of available lines of credit for working capital at December 31, 2020 and 2019 (see Note 8 - Financing).

The Clinic's endowment funds consist of donor-restricted endowments and funds designated by the board as endowment. Income from endowments is restricted for specific purposes. As described in Note 12 - Endowment, under the Clinic spending policy, \$224 from the endowments was available as of January 1, 2021 and \$207 from the endowments was available at January 1, 2020.

Note 3. Medical Service Revenue

Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care. These amounts, representing transaction price, are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Clinic bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Clinic. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The Clinic believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the Clinic's hospital receiving inpatient acute care services. The Clinic measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at

Note 3. Medical Service Revenue (Continued)

a point in time is recognized when goods or services are provided and the Clinic does not believe it is required to provide additional goods or services to the patient.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Clinic has elected to apply the optional exemption provided in *Revenue from Contracts with Customers (Topic 606-10-50-14(a))* and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Clinic determines the transaction price based on standard charges for goods and services provided to patients, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Clinic's policy, and/or implicit price concessions based on historical collection experience.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

- **Medicare:** Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates.
- **Medicaid:** Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.
- **Other:** Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Clinic's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Clinic. In addition, the contracts that the Clinic has with commercial payors also provide for retroactive audit and review of claims.

Note 3. Medical Service Revenue (Continued)

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Clinic also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Clinic estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured, based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to medical service revenue in the period of the change. For the years ended December 31, 2020 and 2019, revenue recognized due to changes in its estimates of transaction price concessions for performance obligations satisfied in prior years was not significant. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense. Bad debt expense for the years ended December 31, 2020 and 2019 was not significant.

Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor, and the Clinic's historical settlement activity, including an assessment to ensure it is probable a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in the transaction price were not significant in 2020 and 2019.

Patients who meet the Clinic's criteria for charity care are provided care without charge or at amounts less than established rates. Such amounts which are determined to qualify as charity care are not reported as revenue.

Notes to Consolidated Financial Statements (In Millions)

Note 3. Medical Service Revenue (Continued)

The composition of medical service revenue based on the regions of the country in which the Clinic operates, its lines of business, and timing of revenue recognition for the years ended December 31, 2020 and 2019 are as follows:

	Year Ended December 31, 2020			
	Midwest	Southeast	Southwest	Total
Hospital	\$ 4,353	\$ 840	\$ 1,041	\$ 6,234
Clinic	2,885	649	727	4,261
Senior Care and Nursing Home	16	—	—	16
Other	50	1	—	51
Total patient care service revenue	7,304	1,490	1,768	10,562
External lab	939	—	—	939
Total medical service revenue	<u>\$ 8,243</u>	<u>\$ 1,490</u>	<u>\$ 1,768</u>	<u>\$ 11,501</u>
Timing of revenue and recognition:				
At time services are rendered	\$ 3,874	650	727	\$ 5,251
Services transferred over time	4,369	840	1,041	6,250
Total	<u>\$ 8,243</u>	<u>\$ 1,490</u>	<u>\$ 1,768</u>	<u>\$ 11,501</u>

	Year Ended December 31, 2019			
	Midwest	Southeast	Southwest	Total
Hospital	\$ 4,412	\$ 770	\$ 1,017	\$ 6,199
Clinic	3,273	652	679	4,604
Senior Care and Nursing Home	18	—	—	18
Other	51	—	—	51
Total patient care service revenue	7,754	1,422	1,696	10,872
External lab	732	—	—	732
Total medical service revenue	<u>\$ 8,486</u>	<u>\$ 1,422</u>	<u>\$ 1,696</u>	<u>\$ 11,604</u>
Timing of revenue and recognition:				
At time services are rendered	\$ 4,056	\$ 652	\$ 679	\$ 5,387
Services transferred over time	4,430	770	1,017	6,217
Total	<u>\$ 8,486</u>	<u>\$ 1,422</u>	<u>\$ 1,696</u>	<u>\$ 11,604</u>

Hospital revenue includes a variety of services mainly covering inpatient procedures requiring overnight stays or outpatient operations that require anesthesia or use of complex diagnostic and surgical equipment, as well as emergency care for traumas and other critical conditions. Clinic revenue includes services mainly focused on the care of outpatients covering primary and specialty health care needs. The Clinic's practice is to record certain radiology, pathology and other hospital related services in the Midwest region as clinic revenue in the amount of \$889 and \$1,110 for the years ended December 31, 2020 and

Note 3. Medical Service Revenue (Continued)

2019, respectively. Examples of revenue at time services are rendered include clinical services, lab and transport, and services transferred over time include hospital and senior care revenue.

The composition of medical service revenue by payor for the years ended December 31 is as follows:

	2020	2019
Medicare	\$ 2,833	\$ 2,819
Medicaid	373	379
Contract	6,779	6,937
Other, including self-pay	1,516	1,469
Total	<u>\$ 11,501</u>	<u>\$ 11,604</u>

The Clinic's practice is to assign a patient to the primary payor and not reflect other uninsured balances (for example, coinsurance and deductibles) as self-pay. Therefore, the payors listed above contain patient responsibility components, such as coinsurance and deductibles.

Financing component:

The Clinic has elected the practical expedient allowed under FASB ASU 2014-09, *Revenue from Contracts with Customers (Topic 606-10-32-18)* and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Clinic's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the Clinic does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

Note 4. Fair Value Measurements

The Clinic holds certain financial instruments that are required to be measured at fair value on a recurring basis. The valuation techniques used to measure fair value under the *Fair Value Measurement (Topic 820)* of the FASB ASC are based upon observable and unobservable inputs. The standard establishes a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

Level 1: Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2: Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the same term of the financial instrument.

Note 4. Fair Value Measurements (Continued)

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers or activity within Levels for the years ended December 31, 2020 and 2019.

The following tables present the financial instruments carried at fair value as of December 31, 2020 and 2019, by caption on the consolidated statements of financial position categorized by the valuation hierarchy and NAV:

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

	December 31, 2020				
	Level 1	Level 2	Level 3	NAV	Total Fair Value
Assets:					
Securities lending collateral	\$ 2	\$ —	\$ —	\$ —	\$ 2
Investments:					
Cash and cash equivalents	1,980	185	—	—	2,165
Fixed-income securities:					
U.S. government	—	450	—	—	450
U.S. government agencies	—	439	—	—	439
U.S. corporate	—	648	15	—	663
Foreign	—	46	—	—	46
Common and preferred stocks:					
U.S.	870	—	—	—	870
Foreign	529	—	25	—	554
Funds:					
Fixed-income	451	10	—	—	461
Equities	830	590	—	—	1,420
Less securities under lending agreement	(38)	—	—	—	(38)
Investments at NAV	—	—	—	7,290	7,290
Total investments	4,622	2,368	40	7,290	14,320
Investments under securities lending agreement	38	—	—	—	38
Other long-term assets:					
Trust receivables	74	29	83	—	186
Technology-based ventures	—	—	92	—	92
Total other long-term assets	74	29	175	—	278
Total assets at fair value	\$ 4,736	\$ 2,397	\$ 215	\$ 7,290	\$ 14,638
Liabilities:					
Securities lending payable	\$ 2	\$ —	\$ —	\$ —	2
Total liabilities at fair value	\$ 2	\$ —	\$ —	\$ —	\$ 2

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

	December 31, 2019				
	Level 1	Level 2	Level 3	NAV	Total Fair Value
Assets:					
Securities lending collateral	\$ 1	\$ —	\$ —	\$ —	\$ 1
Investments:					
Cash and cash equivalents	1,286	18	—	—	1,304
Fixed-income securities:					
U.S. government	—	396	—	—	396
U.S. government agencies	—	376	—	—	376
U.S. corporate	—	436	22	—	458
Foreign	—	44	—	—	44
Common and preferred stocks:					
U.S.	686	—	—	—	686
Foreign	457	—	2	—	459
Funds:					
Fixed-income	505	—	—	—	505
Equities	661	605	—	—	1,266
Less securities under lending agreement	(19)	—	—	—	(19)
Investments at NAV	—	—	—	5,660	5,660
Total investments	3,576	1,875	24	5,660	11,135
Investments under securities lending agreement	19	—	—	—	19
Other long-term assets:					
Trust receivables	70	27	82	—	179
Technology-based ventures	—	—	64	—	64
Total other long-term assets	70	27	146	—	243
Total assets at fair value	\$ 3,666	\$ 1,902	\$ 170	\$ 5,660	\$ 11,398
Liabilities:					
Securities lending payable	\$ 1	\$ —	\$ —	\$ —	1
Total liabilities at fair value	\$ 1	\$ —	\$ —	\$ —	\$ 1

The following is a description of the Clinic's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets and liabilities. Inputs are obtained from various sources, including market participants,

Note 4. Fair Value Measurements (Continued)

dealers and brokers. Level 3 primarily consists of trusts recorded at fair value based on the underlying value of the assets in the trust or discounted cash flow of the expected payment streams.

The trusts reported as Level 3 are primarily perpetual trusts managed by third parties invested in stocks, mutual funds, and fixed-income securities that are traded in active markets with observable inputs and, since the Clinic will never receive the trust assets, these perpetual trusts are reported as Level 3. In addition, technology-based ventures, comprised primarily of shares in start-up companies, are recorded at fair value based on inputs relying on factors such as the financial performance of the company, sales performance, financial projections, sales projections, management representation, industry developments, market analysis, and any other pertinent factors which would affect the fair value or based on the quoted price of an otherwise identical unrestricted security of the same issuer, adjusted for the effect of the restriction.

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Clinic believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2020, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,421	\$ 99	Monthly to annually	30–90 days
Private partnerships (b)	3,869	1,447		
Total alternative investments	<u>\$ 7,290</u>	<u>\$ 1,546</u>		

At December 31, 2019, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 2,706	\$ 64	Monthly to annually	30–90 days
Private partnerships (b)	2,954	1,202		
Total alternative investments	<u>\$ 5,660</u>	<u>\$ 1,266</u>		

Note 4. Fair Value Measurements (Continued)

- (a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry “lockup” restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period, liquidity is generally available monthly, quarterly or annually following a redemption request. Over 90 percent of the investments in this category have at least annual liquidity.
- (b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Clinic’s ownership interest in partners’ capital. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

From time to time, the Clinic invests directly in certain derivative contracts that do not qualify for hedge accounting and are recorded at fair value in investments. Changes in fair value are reported as a component of net unrealized gains or losses in the investment returns. These contracts are used in the Clinic’s investment management program to minimize certain investment risks. During the years ended December 31, 2020 and 2019, the realized and unrealized loss from derivative contracts was not significant.

The carrying values of cash and cash equivalents, short-term investments, accounts receivable, other current assets, and accounts payable are reasonable estimates of their fair value due to the short-term nature of these financial instruments. The estimated fair value of long-term debt, based on quoted market prices for the same or similar issues (Level 2), was \$572 and \$311 more than its carrying value at December 31, 2020 and 2019, respectively. Other long-term assets and liabilities have a carrying value that approximates fair value.

The Clinic uses various external investment managers to diversify the investments. The largest allocation to any investment strategy manager as of December 31, 2020 and 2019 was \$582 (5.7 percent) and \$527 (6.1 percent), respectively.

The Clinic is required to maintain funds held by trustees under bond indentures and other arrangements. The trustee-held investments, which primarily consist of mutual funds, were \$884 and \$757, respectively, at December 31, 2020 and 2019, which includes segregated investments for deferred compensation plans of \$882 and \$739 at December 31, 2020 and 2019, respectively.

At December 31, 2020 and 2019, cash and mutual funds included segregated investments owned by Mayo Foundation for Medical Education and Research, a wholly owned subsidiary of the Clinic, for gift annuity reserves of \$136 and \$131, respectively.

Note 4. Fair Value Measurements (Continued)

The Clinic had internally designated investment balances of \$2,806 and \$2,431 at December 31, 2020 and 2019, respectively, for research, education, and capital replacement and expansion.

Note 5. Securities Lending

The Clinic has an arrangement with its investment custodian to lend Clinic securities to approved brokers in exchange for a fee. Among other provisions that limit the Clinic's risk, the securities lending agreement specifies that the custodian is responsible for lending securities and obtaining adequate collateral from the borrower. Collateral is limited to cash, government securities, and irrevocable letters of credit. Investments are loaned to various brokers and are returnable on demand. In exchange, the Clinic receives collateral. The cash collateral is shown as both an asset and a liability on the consolidated statements of financial position.

At December 31, 2020 and 2019, the aggregate market value of securities on loan under securities lending agreements totaled \$38 and \$19, respectively, and the total value of the collateral supporting the securities was \$39 and \$20, respectively, which represents 104 percent and 105 percent, respectively, of the value of the securities on loan at December 31, 2020 and 2019. The cash portion of the collateral supporting the securities as of December 31, 2020 and 2019 was \$2 and \$1, respectively. Noncash collateral provided to the Clinic is not recorded in the consolidated statements of financial position, as the collateral may not be sold or repledged. The Clinic's claim on such collateral is limited to the market value of loaned securities. In the event of nonperformance by the other parties to the securities lending agreements, the Clinic could be exposed to a loss.

Note 6. Property, Plant and Equipment, Net

Property, plant and equipment, net, at December 31 consisted of the following:

	2020	2019
Land	\$ 316	\$ 303
Buildings and improvements	6,454	6,134
Furniture and equipment	4,249	4,347
	11,019	10,784
Accumulated depreciation and amortization	(6,506)	(6,274)
	4,513	4,510
Construction in progress	451	324
Total property, plant and equipment	\$ 4,964	\$ 4,834

Note 6. Property, Plant and Equipment, Net (Continued)

The above costs and accumulated depreciation include costs for capitalized software, including costs capitalized in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Topic 350)* of the FASB ASC. The total cost for capitalized software was \$914 and \$1,011 at December 31, 2020 and 2019, respectively. The total accumulated amortization was \$558 and \$609 at December 31, 2020 and 2019, respectively. Amortization expense for capitalized software was \$81 for 2020 and 2019.

Note 7. Income Taxes

Most of the income received by the Clinic and its subsidiaries is exempt from taxation under Section 501(a) of the Internal Revenue Code. Some of its subsidiaries are taxable entities, and some of the income received by otherwise exempt entities is subject to taxation as unrelated business income (UBI). The Clinic and its subsidiaries file income tax returns in the U.S., including federal and various state returns, as well as certain foreign jurisdictions. The statutes of limitations for tax years 2017 through 2019 remain open in major U.S. taxing jurisdictions in which the Clinic and subsidiaries are subject to taxation.

The Internal Revenue Service (IRS) performed an examination of the tax and information returns of the Clinic and two subsidiaries and ultimately assessed \$12 in taxes for the years 2003-2012. The results of this audit were ultimately litigated in U.S. District Court. On August 6, 2019, the Court issued a summary judgment in favor of the Clinic. The IRS has appealed this decision. This ruling has been taken into consideration during the Clinic's determination of unrecognized tax benefits.

The Clinic has recorded \$6 reserve for uncertain tax positions, including interest and penalties, did not change significantly during the year ended December 31, 2020. As of December 31, 2020 and 2019, the reserve totaled \$20 and \$14, respectively. It is not anticipated that a significant change in the reserve will occur over the next 12 months.

The Clinic's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The components of tax expense are as follows:

	Year ended December 31	
	2020	2019
Current—federal	\$ 53	\$ 17
Current—state	7	4
	60	21
Deferred—U.S. domestic	(20)	3
Total	\$ 40	\$ 24

Cash payments for income taxes were \$6 and \$34 for the years ended December 31, 2020 and 2019, respectively.

Notes to Consolidated Financial Statements (In Millions)

Note 7. Income Taxes (Continued)

The Clinic records deferred income taxes due to temporary differences between financial reporting and tax reporting for certain assets and liabilities of its taxable activities. The following is a summary of the components of deferred taxes as of December 31:

	2020	2019
Deferred compensation	\$ 12	\$ 11
Pension	15	13
Postretirement benefits	7	5
Net operating loss	16	8
Other	11	9
Total deferred tax asset	61	46
Deferred tax liability	(7)	(6)
Valuation allowance	(13)	(21)
Net deferred tax asset	\$ 41	\$ 19

The Clinic had federal net operating losses of \$46 and \$40 at December 31, 2020 and 2019, respectively.

The Tax Cuts and Jobs Act (TCJA) enacted on December 22, 2017 repealed Net Operating Loss (NOL) carrybacks while permitting indefinite carryforwards. The Coronavirus Aid, Relief and Economic Security Act (CARES Act) enacted on March 27, 2020 temporarily suspended TCJA repeal of NOL carrybacks allowing for NOLs arising in tax years beginning after December 31, 2017 and before January 1, 2021 to be carried back to the five taxable years preceding the taxable year of such loss. The Clinic expects to fully utilize any NOLs arising in tax years beginning after December 31, 2017 and before January 1, 2021 within one or more of the five tax years preceding the tax year of such loss.

The Clinic's valuation allowance for NOLs generated before January 1, 2020 were reversed. At December 31, 2020 the provisional amount recorded related to the reversal of the NOL valuation allowance was \$8.

The Clinic's NOLs generated before January 1, 2020 were remeasured based on the rates at which they are expected to reverse in the carryback periods, which is generally 35 percent. At December 31, 2020, the provisional amount recorded related to the remeasurement of the deferred tax balance was \$5.

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 8. Financing

Long-term debt at December 31 consisted of the following:

		2020	2019
City of Rochester, Minnesota Revenue Bonds issued in various series, subject to variable interest rates to a maximum rate of 15.00% (the average rate was 0.60% in 2020 and 1.50% in 2019), principal due in varying amounts from 2028 through 2052	Variable	\$ 545	\$ 545
City of Rochester, Minnesota Revenue Bonds originally issued at variable interest rate, converted in 2017 to fixed interest rate of 2.20% based on a provision to increase the rate if the federal tax rate is decreased, the rate has been adjusted to 2.67% effective January 1, 2018 through 2027, principal due in varying amounts from 2022 through 2032	Fixed	200	200
City of Rochester, Minnesota Revenue Bonds originally issued with fixed interest rate of 4.74%, converted in 2020 to fixed interest rate of 1.54% until 2030, principal due in varying amounts from 2033 through 2038	Fixed	130	—
City of Rochester, Minnesota Revenue Bonds issued in various series with fixed rates of interest ranging from 4.00% to 4.93%, principal due in varying amounts from 2030 through 2048	Fixed	535	665
City of Rochester, Minnesota Health Care Facilities Revenue Refunding Bonds, series 2016B, issued with fixed interest rate of 5.00%, an effective rate of 2.97% in 2020 and 2019 after amortization of premium, principal due in varying amounts from 2029 through 2036 (unamortized premium of \$55 in 2020 and \$59 in 2019)	Fixed	220	220
Industrial Development Authority of the City of Phoenix, Arizona issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 0.41% in 2020 and 1.38% in 2019), principal due in varying amounts from 2048 through 2052	Variable	180	180
City of Jacksonville, Florida Health Care Facilities Revenue Refunding Bonds, series 2016, issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 0.81% in 2020 and 1.53% in 2019), principal due in varying amounts from 2033 through 2047	Variable	125	125
Mayo Clinic Taxable Bonds issued with fixed interest rates ranging from 3.77% to 4.13%, principal due in varying amounts from 2039 through 2052	Fixed	950	950
Fixed-rate notes and bonds, payable to financial companies, interest rates at 1.80% to 4.71%, principal due in varying amounts from 2025 through 2062	Fixed	915	415
Other notes payable		13	14
Unamortized discounts and premiums, net		52	57
Debt issuance cost		(12)	(13)
		<u>3,853</u>	<u>3,358</u>
Long-term variable-rate debt classified as current		(620)	(710)
Long-term debt subject to mandatory tender for purchase		(135)	—
Current maturities included in other current liabilities		(1)	(1)
Long-term debt, net of current portion		<u>\$ 3,097</u>	<u>\$ 2,647</u>

Note 8. Financing (Continued)

The Clinic's outstanding revenue bond issues are limited obligations of various issuing authorities payable solely by the Clinic pursuant to loan agreements between the borrowing entities and the issuing authorities. Under various financing agreements, the Clinic must meet certain operating and financial performance covenants.

At December 31, 2020, the \$850 of variable-rate bonds consisted of variable-rate demand revenue bonds. In conjunction with the issuance of the variable-rate demand revenue bonds, the Clinic has entered into various bank standby purchase and credit agreements in the amount of \$230 of which \$140 will expire in January 2022 and \$90 will expire in January 2025. Under the terms of these agreements, the bank will make liquidity loans to the Clinic in the amount necessary to purchase a portion of the variable-rate demand revenue bonds if not remarketed. The liquidity loans would be payable over a three- to five-year period, with the first payment due after December 31, 2021. The Clinic has provided self-liquidity for the remaining \$620 of variable-rate demand revenue bonds, which have been classified as current in the accompanying consolidated statements of financial position.

The Clinic's \$135 City of Rochester, Minnesota Revenue Bonds Series 2011 C fixed rate bonds are subject to mandatory tender for purchase on November 15, 2021, and therefore, classified as current.

The \$220 fixed-rate revenue bonds Series 2016B are not callable. The remaining fixed-rate interest revenue bonds are callable from 2021 to 2058 at the option of the Clinic, at a redemption price of 100 percent of the principal amount or at a price based on U.S. Treasury rates at the time of redemption.

In April 2020, the Clinic entered into a five-year bank loan agreement for \$100 at 1.80 percent. In May 2020, the Clinic entered into a seven-year bank loan agreement for \$100 at 1.99 percent. Also in May, the Clinic closed on a private placement transaction with an insurance company in the amount of \$200 with a 3.17 percent fixed rate with a final maturity in 2062. In September 2020, the Clinic closed on a private placement transaction with an insurance company in the amount of \$100 million with a 3.16 percent interest rate with a final maturity in 2060. The proceeds of the private placement and bank loans will be used for general corporate purposes. In addition, in May 2020, the Clinic refunded and modified \$130 of bonds by entering into a direct bank purchase for 10 years at 1.54 percent. The bond modification was accounted for as an extinguishment of debt. The loss on extinguishment was not significant.

The following are scheduled maturities of long-term debt for each of the next five years, assuming the variable-rate demand revenue bonds are remarketed and the standby purchase agreements are renewed. As described above, if such bonds are not remarketed, \$620 may be due in 2021 and \$230 may be due in years from 2022 to 2025.

Years ending December 31:

2021	\$	1
2022		38
2023		36
2024		18
2025		105

Note 8. Financing (Continued)

Interest payments on long-term debt, net of amounts capitalized for 2020 and 2019, totaled \$106 and \$110, respectively. The amount of interest capitalized, net of related interest income, was \$3 during 2020 and \$6 during 2019. Interest expense totaled \$112 and \$111 for 2020 and 2019, respectively.

At December 31, 2020 and 2019, the Clinic had unsecured lines of credit available with banks that totaled \$530, with varying renewable terms and interest up to 2.50 percent over various published rates. There were no amounts drawn during the years ended December 31, 2020 and 2019.

Note 9. Leases

At December 31, 2020 and 2019, the Clinic had operating and finance leases for facilities and certain equipment with lease terms ranging from 1 to 20 years, with some options to extend up to five years or terminate within one year.

Total lease expense for the years ended December 31 consisted of the following:

	2020	2019
Operating lease expense	\$ 37	\$ 34
Finance lease expense:		
Amortization of right-of-use assets	\$ 10	\$ 9
Interest on lease liabilities	1	1
Total finance lease expense	\$ 11	\$ 10
Short-term lease expense	\$ 17	\$ 13

Consolidated supplemental cash flow information related to leases as of December 31 consisted of the following:

	2020	2019
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows for operating leases	\$ 53	\$ 45
Operating cash flows for finance leases	\$ 1	\$ 1
Financing cash flows for finance leases	\$ 15	\$ 8
Right-of-use assets obtained in exchange for lease obligations:		
Operating leases	\$ 11	\$ 37
Finance leases	\$ 12	\$ 15

Notes to Consolidated Financial Statements (In Millions)

Note 9. Leases (Continued)

Consolidated supplemental statement of financial position information related to leases as of the year ended December 31 consisted of the following:

	2020	2019
Operating leases:		
Right-of-use assets	\$ 168	\$ 161
Other current liabilities	\$ 28	\$ 27
Other long-term liabilities	143	136
Total operating lease liabilities	\$ 171	\$ 163
Finance leases:		
Property, plant and equipment, gross	\$ 72	\$ 51
Accumulated depreciation	32	21
Property, plant and equipment, net	\$ 40	\$ 30
Other current liabilities	\$ 9	\$ 10
Other long-term liabilities	27	21
Total finance lease liabilities	\$ 36	\$ 31
Weighted average remaining lease years:		
Operating leases	10.02	8.79
Finance leases	8.06	8.21
Weighted average discount rate:		
Operating leases	3.54 %	2.77 %
Finance leases	3.49 %	3.76 %

Notes to Consolidated Financial Statements (In Millions)

Note 9. Leases (Continued)

Maturities of lease liabilities for the next five years and thereafter consist of the following:

	Operating	Finance
2021	\$ 33	\$ 11
2022	28	6
2023	21	5
2024	20	5
2025	16	3
Thereafter	91	12
Minimum lease payments	209	42
Less amount representing interest	38	6
Net minimum lease payments	\$ 171	\$ 36

Note 10. Board-Designated Funds

Board-designated funds are subject to expenditure for the following purposes for the years ended December 31:

	2020	2019
Research	\$ 1,269	\$ 1,095
Education	296	201
Buildings and equipment	3	3
Charity care	11	10
Clinical	166	146
Other	1,061	976
Total designation for specified purpose	\$ 2,806	\$ 2,431

At December 31, board designated funds were classified as follows:

	2020	2019
Quasi-endowments	\$ 2,694	\$ 2,286
Professional liability reserve	112	99
Other reserves	—	46
Total	\$ 2,806	\$ 2,431

Mayo Clinic**Notes to Consolidated Financial Statements (In Millions)****Note 11. Net Assets with Donor Restrictions**

The Clinic receives contributions in support of research, education and clinical activities. Net assets with donor restrictions were available for the following purposes at December 31:

	2020	2019
Subject to expenditure for specified purposes:		
Research	\$ 443	\$ 366
Education	42	40
Buildings and equipment	226	133
Charity care	36	39
Clinical	58	51
Other	37	15
Total expenditure for specified purposes	842	644
Subject to passage of time:		
Pledges and trusts	470	348
Endowments:		
Perpetual in nature:		
Research	1,078	1,006
Education	229	210
Charity care	14	14
Clinical	195	184
Other	29	29
Pledges and trusts	293	348
Total perpetual in nature	1,838	1,791
Subject to endowment spending policy:		
Research	670	502
Education	320	268
Charity care	36	26
Clinical	135	104
Other	38	32
Total subject to endowment spending policy	1,199	932
Total endowments	3,037	2,723
Total net assets with donor restrictions	\$ 4,349	\$ 3,715

Note 11. Net Assets with Donor Restrictions (Continued)

Net assets were released from donor restrictions as expenditures were made, which satisfied the following restricted purposes for the years ended December 31:

	2020	2019
Research	\$ 162	\$ 161
Education	22	25
Buildings and equipment	22	56
Other	40	28
Total net assets released from donor restrictions	<u>\$ 246</u>	<u>\$ 270</u>

Note 12. Endowment

The Clinic's endowment consists of approximately 2,200 individual funds established for a variety of purposes. The endowment includes both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments (quasi-endowments). Net assets associated with endowment funds, including quasi endowments, are classified and reported based on the existence or absence of donor-imposed restrictions. The Board of Trustees retains the right to re-designate quasi endowments for other purposes.

The Board of Trustees of the Clinic has interpreted the Minnesota State Prudent Management of Institutional Funds Act (SPMIFA) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds, absent explicit donor stipulations to the contrary. As a result of this interpretation, the Clinic retains in perpetuity: (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the perpetual endowment, and (c) accumulations to the perpetual endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

In accordance with SPMIFA, the Clinic considers the following factors in making a determination to appropriate or accumulate donor-restricted funds:

1. The duration and preservation of the fund
2. The purposes of the Clinic and the donor-restricted endowment fund
3. General economic conditions
4. The possible effects of inflation and deflation
5. The expected total return from income and the appreciation of investments
6. Other resources of the Clinic
7. The investment policies of the Clinic

The Clinic has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment, while seeking to maintain purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that the Clinic must hold in perpetuity or for a donor-specified period(s), as well as quasi-

Note 12. Endowment (Continued)

endowments. Under this policy, as approved by the Board of Trustees, the endowment assets are invested in a manner that is intended to produce a real return, net of inflation and investment management costs, of at least five percent over the long term. Actual returns in any given year may vary from this amount.

To satisfy its long-term rate-of-return objectives, the Clinic relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Clinic targets a diversified asset allocation that places a greater emphasis on equity-based and alternative investments to achieve its long-term objective within prudent risk constraints.

The Clinic has a policy of appropriating for distribution each year five percent of its endowment fund's moving average fair value over the prior 36 months as of September 30 of the preceding year in which the distribution is planned. In establishing this policy, the Clinic considered the long-term expected return on its endowment. Accordingly, over the long term, the Clinic expects the current spending policy to allow its endowment to grow at an average of the long-term rate of inflation. This is consistent with the Clinic's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specific term, as well as to provide additional real growth through new gifts and investment return.

At December 31, 2020, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	\$ —	\$ 3,037	\$ 3,037
Quasi-endowments	2,694	—	2,694
Total funds	\$ 2,694	\$ 3,037	\$ 5,731

Notes to Consolidated Financial Statements (In Millions)

Note 12. Endowment (Continued)

Changes in endowment net assets for the year ended December 31, 2020 consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	\$ 2,286	\$ 2,723	\$ 5,009
Investment return:			
Investment income	20	20	40
Net appreciation (realized and unrealized)	345	351	696
Total investment return	365	371	736
Contributions	—	47	47
Appropriation of endowment assets for expenditure	(104)	(104)	(208)
Other changes:			
Transfers to create quasi-endowments	147	—	147
Endowment net assets, end of year	\$ 2,694	\$ 3,037	\$ 5,731

At December 31, 2019, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	\$ —	\$ 2,723	\$ 2,723
Quasi-endowments	2,286	—	2,286
Total funds	\$ 2,286	\$ 2,723	\$ 5,009

Notes to Consolidated Financial Statements (In Millions)

Note 12. Endowment (Continued)

Changes in endowment net assets for the year ended December 31, 2019 consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	\$ 2,124	\$ 2,372	\$ 4,496
Investment return:			
Investment income	31	30	61
Net appreciation (realized and unrealized)	243	235	478
Total investment return	274	265	539
Contributions	—	180	180
Appropriation of endowment assets for expenditure	(246)	(94)	(340)
Other changes:			
Transfers to create quasi endowments	134	—	134
Endowment net assets, end of year	\$ 2,286	\$ 2,723	\$ 5,009

Note 13. Promises to Give

At December 31, outstanding pledges from various corporations, foundations and individuals, included in other receivables and other long-term assets, were as follows:

	2020	2019
Pledges due:		
In less than one year	\$ 234	\$ 185
In one to five years	362	330
In more than five years	45	53
	641	568
Allowance for uncollectible pledges and discounts	(72)	(62)
Total	\$ 569	\$ 506

Estimated cash flows from pledge receivables due after one year are discounted using a risk-adjusted rate, ranging from 1 percent to 6 percent, that is commensurate with the pledges' due dates and established in the year the pledge is received.

Notes to Consolidated Financial Statements (In Millions)

Note 13. Promises to Give (Continued)

The Clinic has received interests in various trusts, primarily split-interest, which are included in other long-term assets. The trusts are recorded at fair value, based on the underlying value of the assets in the trust or discounted cash flow using a risk-adjusted discount rate of 3.56 percent and 4.33 percent at December 31, 2020 and 2019, respectively. During the years ended December 31, 2020 and 2019, there were no contributions recorded related to the split-interest trusts. The balance of the expected payment streams was \$186 and \$179 at December 31, 2020 and 2019, respectively.

Note 14. Functional Expenses

The consolidated financial statements present certain expenses that are attributed to more than one program or supporting function. Therefore, expenses require allocation on a reasonable basis that is consistently applied. Benefits and payroll taxes are allocated based on factors of either salary expense or hours worked. Overhead costs that include professional services, office expenses, information technology, interest, insurance, and other similar expenses are allocated based on a variety of factors, including revenues, hours worked, and salary expense. Costs related to space, including occupancy, depreciation and amortization, and property taxes, are allocated on a square footage basis.

The expenses reported in the consolidated statements of activities for the years ended December 31, 2020 and 2019 supported the following programs and functions:

2020									
	Patient care	Lab and technology ventures	Research	Graduate and other education	General and administrative	Development expenses	Other activities	Total expenses	
Salaries and benefits	\$ 6,757	\$ 173	\$ 608	\$ 305	\$ 50	\$ 19	\$ 152	\$ 8,064	
Supplies and services	2,730	1,006	224	52	9	6	72	4,099	
Depreciation and amortization	514	8	64	12	10	1	2	611	
Facilities	228	5	16	11	14	1	1	276	
Finance and investment	138	1	18	1	1	—	(27)	132	
Total	\$ 10,367	\$ 1,193	\$ 930	\$ 381	\$ 84	\$ 27	\$ 200	\$ 13,182	

2019									
	Patient care	Lab and technology ventures	Research	Graduate and other education	General and administrative	Development expenses	Other activities	Total expenses	
Salaries and benefits	\$ 6,339	\$ 181	\$ 553	\$ 286	\$ 30	\$ 13	\$ 268	\$ 7,670	
Supplies and services	2,815	853	247	68	37	10	46	4,076	
Depreciation and amortization	496	9	59	11	9	1	2	587	
Facilities	240	6	17	11	13	1	2	290	
Finance and investment	128	1	15	1	1	—	(13)	133	
Total	\$ 10,018	\$ 1,050	\$ 891	\$ 377	\$ 90	\$ 25	\$ 305	\$ 12,756	

Note 15. Employee Benefit Programs

The Clinic serves as plan sponsor for several defined benefit pension funds and other postretirement benefits.

Included in other changes in unrestricted net assets at December 31, 2020 and 2019 are the following amounts, respectively, that have not yet been recognized in net periodic cost: unrecognized actuarial losses of \$4,837 and \$4,408 and unrecognized prior service benefit of \$160 and \$229. Actuarial losses are amortized as a component of net periodic pension cost, only if the losses exceed ten percent of the greater of the projected benefit obligation or the fair value of plan assets. Unrecognized prior service benefits are amortized on a straight-line basis over the estimated life of plan participants. The unrecognized actuarial losses and prior service benefit included in net assets are expected to be recognized in net periodic pension cost during the year ended December 31, 2021, in the amount of \$338 and \$51, respectively.

Changes in plan assets and benefit obligations recognized in unrestricted net assets during 2020 and 2019 included the following:

	2020	2019
Current-year actuarial gain (loss)	\$ (701)	\$ (1,121)
Amortization of actuarial loss	274	152
Amortization of prior service credit	(69)	(69)
Pension and other postretirement benefit adjustments	\$ (496)	\$ (1,038)

Pension plans:

Obligations and funded status: The following is a summary of the changes in the benefit obligation and plan assets, the resulting funded status of the qualified and nonqualified pension plans, and accumulated benefit obligation as of and for the years ended December 31:

Note 15. Employee Benefit Programs (Continued)

	2020	2019
Change in projected benefit obligation:		
Benefit obligation, beginning of year	\$ 10,705	\$ 8,866
Service cost	553	447
Interest cost	371	374
Actuarial loss	1,388	1,493
Benefits paid	(657)	(476)
Estimated benefit obligation at end of year	<u>\$ 12,360</u>	<u>\$ 10,705</u>

Change in plan assets:		
Fair value of plan assets, beginning of year	\$ 9,334	\$ 8,084
Actual return on plan assets	1,409	1,180
Employer contributions	556	545
Benefits paid	(657)	(476)
Fair value of plan assets at end of year	<u>\$ 10,642</u>	<u>\$ 9,334</u>

	2020	2019
Funded status of the plans	<u>\$ (1,718)</u>	<u>\$ (1,371)</u>
Accumulated benefit obligation	<u>\$ (11,596)</u>	<u>\$ 10,173</u>

Amounts recognized in the consolidated statements of financial position consist of the following at December 31:

	2020	2019
Noncurrent liabilities	\$ (1,718)	\$ (1,371)
Net amount recognized	<u>\$ (1,718)</u>	<u>\$ (1,371)</u>

Note 15. Employee Benefit Programs (Continued)

Components of net periodic benefit cost are as follows at December 31:

	2020	2019
Service cost	\$ 553	\$ 447
Interest cost	371	374
Expected return on plan assets	(678)	(635)
Amortization of unrecognized:		
Prior service benefit	(50)	(50)
Net actuarial loss	244	142
Net periodic benefit cost	<u>\$ 440</u>	<u>\$ 278</u>

Plan assets: The largest of the pension funds is the Mayo Clinic Master Retirement Trust Plan, which holds \$10,519 of the \$10,642 in combined plan assets at December 31, 2020, and \$9,216 of the \$9,334 in combined plan assets at December 31, 2019. The investment policies described below apply to the Mayo Clinic Master Retirement Trust Plan (the Plan).

The Plan employs a global, multi-asset approach in managing its retirement plan assets. This approach is designed to maximize risk-adjusted returns over a long-term investment horizon, consistent with the nature of the pension liabilities being funded. The plan asset portfolio's target allocation for total return investment strategies, which include public equities, private equities, absolute return, and real assets, is 82.5 percent. The portfolio's target fixed-income exposure is 17.5 percent. The fixed-income exposure may include the use of long-term interest rate swap contracts structured to increase the portfolio's interest rate sensitivity and thereby provide a hedge of the plan liabilities resulting from falling long-term interest rates. Investments in private equities, real assets, and absolute return strategies are held to improve diversification and thereby enhance long-term, risk-adjusted returns. However, recognizing that these investments are not as liquid as publicly traded stocks and bonds, portfolio investment policies limit overall exposure to these assets. The portfolio's allocation to private equities and real assets is limited to a maximum of 30 percent (with a target allocation of 22.5 percent), and exposure to absolute return strategies is limited to a maximum of 35 percent (with a target of 27.5 percent). The Clinic reviews performance, asset allocation, and risk management reports for plan asset portfolios on a monthly basis.

Mayo Clinic

Notes to Consolidated Financial Statements (In Millions)

Note 15. Employee Benefit Programs (Continued)

The fair values of the Plan's assets at December 31, 2020, by asset category, are as follows:

Assets	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	NAV	Total
Cash and cash equivalents	\$ 616	\$ 41	\$ —	\$ —	\$ 657
Fixed-income securities:					
U.S. government	—	146	—	—	146
U.S. government agencies	—	126	—	—	126
U.S. corporate	—	406	5	—	411
Foreign	—	33	—	—	33
Common and preferred stocks:					
U.S.	926	—	—	—	926
Foreign	639	—	—	—	639
Funds:					
Fixed-income	132	10	—	—	142
Equities	42	654	—	—	696
Foreign	79	—	—	—	79
Investments at NAV	—	—	—	6,664	6,664
Total investments	\$ 2,434	\$ 1,416	\$ 5	\$ 6,664	\$ 10,519

The fair values of the Plan's assets at December 31, 2019, by asset category, are as follows:

Assets	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	NAV	Total
Cash and cash equivalents	\$ 423	\$ 265	\$ —	\$ —	\$ 688
Fixed-income securities:					
U.S. government	—	100	—	—	100
U.S. government agencies	—	146	—	—	146
U.S. corporate	—	344	7	—	351
Foreign	—	37	—	—	37
Common and preferred stocks:					
U.S.	793	—	—	—	793
Foreign	567	—	—	—	567
Funds:					
Fixed-income	119	—	—	—	119
Equities	36	615	—	—	651
Foreign	67	—	—	—	67
Investments at NAV	—	—	—	5,697	5,697
Total investments	\$ 2,005	\$ 1,507	\$ 7	\$ 5,697	\$ 9,216

Note 15. Employee Benefit Programs (Continued)

The following is a description of the Plan's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Inputs are obtained from various sources, including market participants, dealers and brokers.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers in 2020 or 2019.

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2020, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,613	\$ 99	Monthly to annually	30–90 days
Private partnerships (b)	3,051	1,281		
	<u>\$ 6,664</u>	<u>\$ 1,380</u>		

At December 31, 2019, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,141	\$ 64	Monthly to annually	30–90 days
Private partnerships (b)	2,556	1,185		
	<u>\$ 5,697</u>	<u>\$ 1,249</u>		

Note 15. Employee Benefit Programs (Continued)

- (a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry “lockup” restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period, liquidity is generally available monthly, quarterly or annually following a redemption request. Over 90 percent of the investments in this category have at least annual liquidity.
- (b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Plan’s ownership interest in partners’ capital. These investments cannot be redeemed with the funds. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

No plan assets are expected to be returned to the employer during 2021.

Other postretirement benefits:

Obligations and funded status: A summary of the changes in the benefit obligation and plan assets and the resulting funded status of the other postretirement plans is as follows as of and for the years ended December 31:

Notes to Consolidated Financial Statements (In Millions)

Note 15. Employee Benefit Programs (Continued)

	2020	2019
Change in projected benefit obligation:		
Benefit obligation at beginning of year	\$ 1,180	\$ 1,008
Service cost	9	9
Interest cost	39	43
Plan participants' contributions	31	30
Amendments	—	—
Medicare subsidy	3	3
Actuarial loss	46	178
Benefits paid	(80)	(91)
Estimated benefit obligation at end of year	<u>\$ 1,228</u>	<u>\$ 1,180</u>
Change in plan assets:		
Fair value of plan assets at beginning of year	\$ —	\$ —
Employer contributions	49	58
Plan participants' contributions	31	30
Medicare subsidy	—	3
Benefits paid	(80)	(91)
Fair value of plan assets at end of year	<u>\$ —</u>	<u>\$ —</u>
Funded status of the plan	<u>\$ (1,228)</u>	<u>\$ (1,180)</u>

Amounts recognized in the consolidated statements of financial position for postretirement benefits consist of the following at December 31:

	2020	2019
Current liabilities	\$ (49)	\$ (51)
Noncurrent liabilities	(1,179)	(1,129)
Net amount recognized	<u>\$ (1,228)</u>	<u>\$ (1,180)</u>

Notes to Consolidated Financial Statements (In Millions)

Note 15. Employee Benefit Programs (Continued)

Components of net periodic benefit cost for other postretirement benefits are as follows for the years ended December 31:

	2020	2019
Service cost	\$ 9	\$ 9
Interest cost	39	43
Amortization of:		
Unrecognized prior service benefit	(19)	(19)
Unrecognized net actuarial loss	30	11
Net periodic benefit cost for other postretirement benefits	<u>\$ 59</u>	<u>\$ 44</u>

The Clinic has concluded that the prescription drug benefits under its defined benefit postretirement plan are actuarially equivalent to Medicare Part D under the Medicare Modernization Act (the Act) and that the Clinic will receive the subsidy available under the Act.

The following reflects the expected future Medicare Part D subsidy receipts:

Years ending December 31:	
2021	\$ 3
2022	3
2023	3
2024	3
2025	3
2026–2030	16

Plan trend rates are the annual rates of increase expected for the benefits payable from the plan; these rates include health care cost trends plus the leveraging effect of plan design. The assumed plan trend rate is 5.50 percent. A one-percentage-point change in the assumed health care cost trend rate would have the following effects:

	One-Percentage- Point Increase	One-Percentage- Point Decrease
Effect on total service and interest cost components in 2020	\$ 2	\$ (2)
Effect on postretirement benefit obligation at December 31, 2020	48	(41)

Note 15. Employee Benefit Programs (Continued)**Pension and postretirement benefits:**

Assumptions: Weighted-average assumptions used to determine pension and postretirement benefit obligations at the measurement date are as follows:

	Pension Benefits		Postretirement Benefits	
	2020	2019	2020	2019
Discount rate	2.91%	3.56%	2.70%	3.41%
Rate of compensation increase	3.70%	3.58%	N/A	N/A

Weighted-average assumptions used to determine net periodic pension and postretirement benefit cost are as follows:

	Pension Benefits		Postretirement Benefits	
	2020	2019	2020	2019
Discount rate	3.56%	4.33%	3.41%	4.35%
Expected long-term return on plan assets	7.50%	7.50%	N/A	N/A
Rate of compensation increase	3.58%	3.53%	N/A	N/A

The Clinic utilizes a building block approach in determining the expected long-term rate of return for its plan assets. First, historical data on individual asset class returns are studied. Next, the historical correlation among and between asset class returns is studied under both normal conditions and in times of market turbulence. Then, various mixes of asset classes are considered under multiple long-term investment scenarios. Finally, after considering liquidity concerns related to the use of certain alternative asset classes, the plan sponsor selects the portfolio blend that it believes will produce the highest expected long-term return on a risk-adjusted basis.

Cash flows:

Contributions: The Clinic expects to contribute \$373 to its pension plans in 2021.

Note 15. Employee Benefit Programs (Continued)

Estimated future benefit payments: The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

	Pension Benefits	Postretirement Benefits
Years ending December 31:		
2021	\$ 663	\$ 50
2022	615	53
2023	607	55
2024	600	58
2025	642	59
2026–2030	3,175	317

In addition to the defined benefit plans, the Clinic sponsors various defined contribution benefit plans. Expense recognized by the Clinic for those plans was \$117 and \$110 for 2020 and 2019, respectively.

Note 16. General and Professional Liability Insurance

The Clinic insures substantially all general and professional liability risks through a combination of a wholly owned captive insurance company and self-insurance. The insurance program combines various levels of self-insured retention with excess commercial insurance coverage. Actuarial consultants have been retained to assist in the estimation of outstanding general and professional liability losses.

The Clinic's general and professional liability as reported in the accompanying consolidated statements of financial position was \$118 and \$111 at December 31, 2020 and 2019, respectively. Provisions for the general and professional liability risks are based on an actuarial estimate of losses using the Clinic's actual loss data, adjusted for industry trends and current conditions, and considering an evaluation of claims by the Clinic's legal counsel. The provision includes estimates of ultimate costs for both reported claims and claims incurred but not reported.

Notes to Consolidated Financial Statements (In Millions)

Note 16. General and Professional Liability Insurance (Continued)

Activity in the liability is summarized as follows for the years ended December 31:

	2020	2019
Balance, beginning of year	\$ 111	\$ 101
Incurred related to captive insurance company liability:		
Current year	26	23
Prior years	(4)	4
Total incurred	22	27
Paid related to captive insurance company liability:		
Current year	—	(1)
Prior years	(19)	(15)
Total paid	(19)	(16)
Net change in self-insurance liability	4	(1)
Balance, end of year	\$ 118	\$ 111

Note 17. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities

At December 31, other receivables consisted of the following:

	2020	2019
Pledges receivable	\$ 234	\$ 185
Grants receivable	134	114
Other tax receivable	31	—
Royalty receivable	15	32
Other	162	127
Total other receivables	\$ 576	\$ 458

At December 31, other current assets consisted of the following:

	2020	2019
Inventories	\$ 186	\$ 149
Prepaid expenses	66	52
Total other current assets	\$ 252	\$ 201

Notes to Consolidated Financial Statements (In Millions)

Note 17. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities (Continued)

At December 31, other long-term assets consisted of the following:

	2020	2019
Pledges receivable	\$ 335	\$ 321
Trust receivables	186	179
Operating lease right-of-use asset	168	161
Oil and gas interests	165	155
Technology-based ventures	92	64
Investment in joint venture	89	—
Long-term portion of deferred tax asset	20	27
Other	149	116
Total other long-term assets	<u>\$ 1,204</u>	<u>\$ 1,023</u>

At December 31, other current liabilities consisted of the following:

	2020	2019
Oil and gas liability	\$ 85	\$ 89
Other taxes	81	86
Current portion of long-term disability	38	35
Current portion of professional and general liability	35	31
Short-term disability	33	32
Real estate tax accrual	28	24
Operating lease liability	28	27
Refunds/recoupments	21	24
Current portion of workers' compensation liability	11	17
Finance lease liability	9	10
Other	101	98
Total other current liabilities	<u>\$ 470</u>	<u>\$ 473</u>

Notes to Consolidated Financial Statements (In Millions)

Note 17. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities (Continued)

At December 31, other long-term liabilities consisted of the following:

	2020	2019
Deferred compensation	\$ 882	\$ 739
Long-term disability	211	182
Operating lease liability	143	136
Electronic medical record	105	110
Retirement community obligations	87	38
Professional and general liability	83	80
Gift annuities	67	69
Deferred gain	56	—
Financing obligations	54	57
Trust obligations	53	47
Asset retirement obligation	52	22
Workers' compensation liability	32	26
Finance lease liability	27	21
Contract deposit	22	22
Other	90	85
Total other long-term liabilities	<u>\$ 1,964</u>	<u>\$ 1,634</u>

Note 18. Other Revenue

For the years ended December 31, other revenue consisted of the following:

	2020	2019
Retail pharmacy sales	\$ 393	\$ 346
Provider relief funds and other support	199	—
Royalties	129	117
Retail stores	57	60
Technology commercialization, health information and medical products	49	69
Oil- and gas-producing activities	46	28
Cafeteria revenue	26	37
Graduate medical and other education revenue	22	41
Other	300	320
Total other revenue	<u>\$ 1,221</u>	<u>\$ 1,018</u>

Note 19. Commitments and Contingencies

The Clinic has various construction projects in progress related to patient care, research, and educational facilities. The estimated costs committed to complete the various projects at December 31, 2020 is \$1,363, all of which is expected to be expended over the next three to five years.

While the Clinic is self-insured for a substantial portion of its general and workers' compensation liabilities, the Clinic maintains commercial insurance coverage against catastrophic loss. Additionally, the Clinic maintains a self-insurance program for its long-term disability coverage. The provision for estimated self-insured claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported.

The Clinic is a defendant in various lawsuits arising in the ordinary course of business and records an estimated liability for probable claims. Although the outcome of these lawsuits cannot be predicted with certainty, management believes the ultimate disposition of such matters will not have a material effect on the Clinic's consolidated financial position or consolidated statement of activities.

Note 20. COVID-19

In March 2020, the World Health Organization (WHO) declared the novel coronavirus disease (COVID-19) a pandemic. The Center for Disease Control (CDC) confirmed its spread to the United States and it was declared a national public health emergency, followed by several state emergency declarations, and the Centers for Medicare and Medicaid Services (CMS) issuing guidance regarding elective procedures. Several national and international travel restrictions were put in place and the governors in the states in which the Clinic has operations issued executive orders postponing non-essential or elective surgeries. In response, the Clinic took appropriate measures to respond to the anticipated revenue shortfalls; including reducing supplemental and contract workforce, halting most construction projects, deferring or delaying most strategic initiatives, and announcing temporary salary and staff reductions. In May 2020, elective surgeries were resumed as governmental order restrictions on elective surgeries were modified.

Beginning in April 2020, the Clinic started receiving provider relief funds totaling \$338 from various provisions in the CARES Act of which \$182 was recognized as other revenue in the consolidated statement of activities and the remaining \$156 was returned in December 2020. Additionally, in April 2020, the Clinic received \$915 of Medicare advance payments as part of the CMS Accelerated and Advance Payments Program, and subsequently returned the \$915 of the CMS Accelerated and Advance Program payments in July 2020.

The Clinic was well-prepared and ready to treat patients with COVID-19 across the organization, especially those with serious or complex medical conditions. By the end of May 2020, the governors had relaxed restrictions on non-essential or elective surgeries. The Clinic resumed to safely caring for patients facing non-COVID-19 conditions who are in need of the unique and specialized care offered by the Clinic. However, COVID-19 could still negatively affect the operating margins and financial results of the Clinic, as the duration of the pandemic is unknown.

Note 21. Joint Venture and Related Party

The Clinic has entered into a joint venture agreement with Abu Dhabi Health Services Company PJSC (SEHA) to operate Sheikh Shakhbout Medical City (SSMC), a 741-bed hospital in the United Arab Emirates. The Clinic funded a 25% equity position in the joint venture (SSMC LLC) with cash and other intangibles. The Clinic's equity position is accounted for using the equity method of accounting for investments. In addition to the joint venture agreement, the Clinic has entered into a hospital expertise agreement, brand license agreement, and research contribution agreement with SSMC all executed on November 25, 2019.

The joint venture has an initial commitment period of twenty years and may be extended by ten years.

The Clinic had a \$150 conditional pledge from the joint venture at December 31, 2020 and 2019. The brand license and hospital expertise agreements are effective January 2021.